Drug Fever Due to Favipiravir Administration for the Treatment of a COVID-19 Patient.

Tawara, Junsuke; Uehara, Takanori; Sakao, Seiichiro; Igari, Hidetoshi; Taniguchi, Toshibumi; Kasai, Hajime; Takayanagi, Shin; Yahaba, Misuzu; Shimada, Ryo; Ikusaka, Masatomi

Tawara, Junsuke; Uehara, Takanori; Sakao, Seiichiro; Igari, Hidetoshi; Taniguchi, Toshibumi; Kasai, Hajime; Takayanagi, Shin; Yahaba, Misuzu; Shimada, Ryo; Ikusaka, Masatomi.

Afiliação

Tawara J; Department of General Medicine, Chiba University Hospital, Japan.
Uehara T; Department of General Medicine, Chiba University Hospital, Japan.
Sakao S; Department of Respiratory Medicine, Chiba University Hospital, Japan.
Igari H; Department of Infectious Diseases, Chiba University Hospital, Japan.
Taniguchi T; Department of Infectious Diseases, Chiba University Hospital, Japan.
Kasai H; Department of Respiratory Medicine, Chiba University Hospital, Japan.
Takayanagi S; Department of Infectious Diseases, Chiba University Hospital, Japan.
Yahaba M; Department of Infectious Diseases, Chiba University Hospital, Japan.
Shimada R; Department of General Medicine, Chiba University Hospital, Japan.
Ikusaka M; Department of General Medicine, Chiba University Hospital, Japan.

Intern Med ; 60(7): 1115-1117, 2021 Apr 01.

Article em En | MEDLINE | ID: mdl-33583886

Assuntos

COVID-19; Preparações Farmacêuticas; Amidas; Antivirais/efeitos adversos; Febre/induzido quimicamente; Humanos; Masculino; Pessoa de Meia-Idade; Pirazinas; SARS-CoV-2

Palavras-chave

COVID-19; drug fever; favipiravir; hyperuricemia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Preparações Farmacêuticas / COVID-19 Limite: Humans / Male / Middle aged Idioma: En Revista: Intern Med Assunto da revista: MEDICINA INTERNA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Japão

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google